

147 RECEIVED 22 MAR 2006


#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Habib) ATTORNEY DOCKET: 04343407
ZAGHOUBANI et al.)
SERIAL NO.: 10/510,411) GROUP ART UNIT: Unknown
FILED: October 6, 2004) EXAMINER: Unknown
TITLE: TREATMENT OF TYPE-1 DIABETES BEFORE AND AFTER
EXPRESSION OF PREDISPOSITION MARKERS
DATE: March 22, 2006 CUSTOMER NO.: 26565

Certificate of Mailing by "Express Mail"

"Express Mail" mailing label No. EV548618082US. Date of Deposit: March 22, 2006.
I hereby certify that this paper (and its recited enclosures) or fee is being deposited with the
United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to: Commissioner for Patents, PO Box 1450,
Alexandria, VA 22313-1450.


(signature of person mailing paper or fee)

Timothy M. Hubalik

(typed name of person mailing paper or fee)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO NOTICE TO FILE MISSING PARTS
OF NONPROVISIONAL APPLICATION

1. ☒ This replies to the Notice to File Missing Parts of Nonprovisional Application mailed January 4, 2006. A copy of the Notice to File Missing Parts of Nonprovisional Application is enclosed.
2. ☒ The Oath or Declaration was requested. Copies of the Response to Notification of Missing Requirements and Combined Declaration and Power of Attorney submitted on September 12, 2005 in compliance with 37 CFR 1.63 and return receipt postcard are enclosed.
3. ☒ The sequence disclosures contained in this application do not comply with the requirements as set forth in 37 CFR 1.822-1.823. A copy of the Raw Sequence Listing Error Report is enclosed. Applicants submit herewith an Amendment to Sequence Listing, paper and computer readable copies of the corrected Sequence Listing, a CFR

Verification and Summary Report and Error Listing, and a Statement under 37 CFR 1.821-1.825.

4. ☒ This filing is by a ☐ large entity,
☒ small entity,
☒ which was declared at the time of filing the application.
☐ which is being declared now, and a separate refund request for the application fee accompanies this paper.

5. Extension of Time

- a. ☒ Applicant petitions for an extension of time for 1 month, including payment of the appropriate fee in the amount of \$65.00. If an additional extension of time is required, please consider this a petition therefore.

6. Completion Fees

- a. The surcharge for filing the required oath/declaration and drawings is \$ 65.00 for small entity.

7. Total Fees Due

Completion Fees: \$ 65.00
Extension Fees: \$ 60.00

TOTAL FEE DUE: \$125.00

8. Payment of Fees

Repln. Ref: 05/04/2006 SAHME1 0008324300
DAH:130019 Name/Number: 10510411
FC: 9204


- ☒ Attached is a check in the amount of \$125.00
☐ Authorization is hereby made to charge the amount of to Deposit Account No. 13-0019
☒ Charge any additional fees required by this paper or credit any overpayment to Deposit Account No. 13-0019. A duplicate paper is attached for this purpose.

03/28/2006 GFREY1 00000159 10510411

01-FC:2617
02-FC:2251

~~65.00 OP~~
60.00 OP

Respectfully submitted,



David B. Fournier
Reg. No. 51,696

Adjustment date: 05/04/2006 SAHME1
03/28/2006 GFREY1 00000159 10510411
01-FC:2617

MAYER, BROWN, ROWE & MAW LLP
P.O. Box 2828
Chicago, IL 60690-2828
Telephone: (312) 701-8034
Facsimile: (312) 706-9000

04343407



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/510,411	Habib Zaghouani	04343407

INTERNATIONAL APPLICATION NO.

PCT/US03/10700

I.A. FILING DATE	PRIORITY DATE
04/08/2003	04/09/2002

26565

JAM / DBP
 MAYER, BROWN, ROWE & MAW LLP
 P.O. BOX 2828
 CHICAGO, IL 60690-2828

Rec'd (OAH/De/Seq Ltr)
3-4-06 / 8-4-06
AT

CONFIRMATION NO. 8513

371 FORMALITIES LETTER



OC000000015993346

Date Mailed: 01/04/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 10/06/2004
- Copy of the International Search Report filed on 10/06/2004
- Biochemical Sequence Diskette filed on 10/06/2004
- U.S. Basic National Fees filed on 10/06/2004
- Priority Documents filed on 10/06/2004

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

- \$65 Surcharge.

RECEIVED
 JAN 9 2006

MAYER, BROWN, ROWE & MAW
 DOCKETING
Cent.D

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/510,411	PCT/US03/10700	04343407

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/510411

Applicant: Zaghouani et al.

Filed: October 6, 2004

Title: TREATMENT OF TYPE 1 DIABETES BEFORE AND
AFTER EXPRESSION OF PREDISPOSITION MARKERS

Art Unit: Unknown

Examiner: Unknown

Docket No.: 04343407

Customer No.: 26565

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY
"EXPRESS MAIL"

"Express Mail" mailing label number
EV548618992US

Date of Deposit: September 12, 2005

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail Post Office to Addressee" under 37
CFR 1.10 on the date indicated above and is
addressed to COMMISSIONER FOR PATENTS,
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

typed or printed name of person mailing paper or
fee:


Robin Cali

RESPONSE TO NOTIFICATION OF
MISSING REQUIREMENTS UNDER 35 U.S.C. 371

Dear Sir:

1. ☒ This replies to the Notification of Missing Requirements mailed on May 12, 2005. A copy of the Notification of Missing Requirements is enclosed.
2. ☒ The Oath or Declaration was missing. A copy of the Combined Declaration and Power of Attorney is being submitted under 37 CFR 1.51(b)(2) and 1.53(f).
3. ☒ This filing is by a ☐ large entity,
☒ small entity,
☒ which was declared at the time of filing the application.
☐ which is being declared now, and a separate refund
request for the application fee accompanies this paper.
4. Completion Fees
 - a. The surcharge for filing the required oath/declaration is \$65.00 for small entity.
5. Extension of Time
 - a. ☒ Applicants petition for an extension of time for two months, including payment of the appropriate fee in the amount of \$225.00. If an additional extension of time is required, please consider this a petition therefore.

- ☐ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

6. Total Fees Due


Completion Fees: \$65.00
Extension Fees: \$225.00

TOTAL FEE DUE: \$290.00

7. Payment of Fees

- ☐ Attached is a check in the amount of _____.
- ☒ Authorization is hereby made to charge the amount of \$290.00 to Deposit Account No. 13-0019.
- ☒ Charge any additional fees required by this paper or credit any overpayment to Deposit Account No. 13-0019. A duplicate paper is attached for this purpose.

Respectfully submitted,



Joseph A. Mahoney
Reg. No. 38,956

Date: September 12, 2005

MAYER, BROWN, ROWE & MAW LLP
P.O. Box 2828
Chicago, Illinois 60690-2828
Telephone: (312) 701-8979
Facsimile: (312) 706-9000

COMBINED DECLARATION AND POWER OF ATTORNEY

**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)**

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a continuation application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

**TREATMENT OF TYPE 1 DIABETES BEFORE AND AFTER
EXPRESSION OF PREDISPOSITION MAKERS**

SPECIFICATION IDENTIFICATION

The specification of which was filed October 6, 2004 and accorded Application No. 10/510,411.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56 .

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. Section 119(e))**

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER

60/371,663

FILING DATE

April 9, 2002

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. SECTION 120.**

I hereby claim the benefit, under Title 35, United States Code, Section 120, of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information that occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. SECTION 120:				
U.S. APPLICATIONS		Status		
U.S. APPLICATIONS	U.S. FILING DATE	Patented	Pending	Abandoned

PCT APPLICATION DESIGNATING THE U.S.		
PCT APPLICATION NO.	PCT FILING DATE	PRIORITY CLAIMED UNDER 35 USC 119
PCT/US2003/010700	April 8, 2003	YES

CLAIM FOR FOREIGN PRIORITY BENEFITS
(35 U.S.C. Section 119(a)-(d) or (f), or 365(b) or (365(a))

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America,

listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION NUMBERS(S)			
FOREIGN APPLICATION NO.	COUNTRY	FILING DATE	CERTIFIED COPY ATTACHED?

POWER OF ATTORNEY

I hereby appoint practitioners of Mayer, Brown, Rowe & Maw LLP to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, associated with the following CUSTOMER NUMBER:

26565
26565

SEND CORRESPONDENCE TO:

26565
26565

Mayer, Brown, Rowe & Maw LLP
P.O. Box 2828
Chicago, IL 60690-2828
USA

DIRECT TELEPHONE CALLS TO:

Joseph A. Mahoney, Reg. No. 38,956
(312) 701-8979

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Inventor's Name: Habib Zaghouni

Inventor's signature 

Date 09/02/2005

Country of Citizenship: US
Residence: Columbia, MO
Post Office Address: 1608 Brookfield Manor
Columbia, MO 65203

Inventor's Name: Randal Keith Gregg

Inventor's signature 

Date 8-26-2005

Country of Citizenship: US
Residence: Charlottesville, VA
Post Office Address: 112 Loma Lane
Charlottesville, VA 22902

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/510,411
Source: PT/10
Date Processed by STIC: 4/21/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/510,411

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.

- 3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped

 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.

- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000

- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
 Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

- 13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



PCT

RAW SEQUENCE LISTING

DATE: 04/21/2005

PATENT APPLICATION: US/10/510,411

TIME: 09:57:42

Input Set : A:\Type-I Diabetes.ST25.txt

Output Set: N:\CRF4\04212005\J510411.raw

3 <110> APPLICANT: The Curators of the University of Missouri
 5 <120> TITLE OF INVENTION: Treatment of Type I Diabetes Before and After Expression of
 6 Predisposition Markers
 8 <130> FILE REFERENCE: 04343407
 10 <140> CURRENT APPLICATION NUMBER: 10/510,411
 11 <141> CURRENT FILING DATE: 2004-10-06
 13 <150> PRIOR APPLICATION NUMBER: 60/371,663
 14 <151> PRIOR FILING DATE: 2002-04-09
 16 <150> PRIOR APPLICATION NUMBER: PCT/US2003/010700
 17 <151> PRIOR FILING DATE: 2002-04-08
 19 <160> NUMBER OF SEQ ID NOS: 5
 21 <170> SOFTWARE: PatentIn version 3.2
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 15
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Gallus sp.
 29 <220> FEATURE:
 30 <221> NAME/KEY: MISC_FEATURE
 31 <222> LOCATION: (9)..(23) *only 15 amino acids in this sequence*
 32 <223> OTHER INFORMATION: Insulin is conserved among species
 34 <400> SEQUENCE: 1
 36 Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Gln Arg Gly
 37 1 5 10 15
 40 <210> SEQ ID NO: 2
 41 <211> LENGTH: 15
 42 <212> TYPE: PRT
 43 <213> ORGANISM: various species *see item 10 on (Ever summary sheet)*
 46 <220> FEATURE:
 47 <221> NAME/KEY: MISC_FEATURE
 48 <222> LOCATION: (11)..(25)
 49 <223> OTHER INFORMATION: Amino acid residues 11-25 of HEL.
 51 <400> SEQUENCE: 2
 53 Ala Met Lys Arg His Gly Leu Asp Asn Tyr Arg Gly Arg Ser Leu
 54 1 5 10 15
 57 <210> SEQ ID NO: 3
 58 <211> LENGTH: 20
 59 <212> TYPE: PRT
 60 <213> ORGANISM: various species
 63 <220> FEATURE:
 64 <221> NAME/KEY: MISC_FEATURE
 65 <222> LOCATION: (524)..(543)
 66 <223> OTHER INFORMATION: Amino acid residues 524 -543 of GAD 65
 68 <400> SEQUENCE: 3

pp 1-2
 Does Not Comply
 Detected Diskette Needle

*do you mean
 (1)..(15)?*

*or (9)..(23)
 of another,
 larger sequence*

*if this
 sequence was
 synthesized from*

*various species,
 use <213> Artificial Sequence
 and <220> (header only)
 <223> Synthesized*

RAW SEQUENCE LISTING

DATE: 04/21/2005

PATENT APPLICATION: US/10/510,411

TIME: 09:57:42

Input Set : A:\Type-I Diabetes.ST25.txt

Output Set: N:\CRF4\04212005\J510411.raw

70 Ser Arg Leu Ser Lys Val Ala Pro Val Ile Lys Ala Arg Met Met Gln

71 1 5 10 15

74 Tyr Gly Thr Thr

75 20

78 <210> SEQ ID NO: 4

79 <211> LENGTH: 15

80 <212> TYPE: PRT

81 <213> ORGANISM: various species

84 <220> FEATURE:

85 <221> NAME/KEY: MISC_FEATURE

86 <222> LOCATION: (206)..(220)

87 <223> OTHER INFORMATION: Amino Acid Residues 206-220 of GAD 65

89 <400> SEQUENCE: 4

91 Thr Tyr Glu Ile Ala Pro Val Phe Val Leu Leu Glu Tyr Val Thr

92 1 5 10 15

95 <210> SEQ ID NO: 5

96 <211> LENGTH: 18

97 <212> TYPE: PRT

98 <213> ORGANISM: various species

101 <220> FEATURE:

102 <221> NAME/KEY: MISC_FEATURE

103 <223> OTHER INFORMATION: Flanking regions

105 <400> SEQUENCE: 5

107 Tyr Phe Cys Ala Arg Ser Tyr Tyr Ser Gly Asp Met Tyr Cys Phe Asp

108 1 5 10 15

111 Tyr Trp

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/510,411

DATE: 04/21/2005

TIME: 09:57:43

Input Set : A:\Type-I Diabetes.ST25.txt

Output Set: N:\CRF4\04212005\J510411.raw